Get the Stockscreener App
71.70
0.20%
0.14
After Hours:
71.70
Avidity Biosciences Inc stock is traded at $71.70, with a volume of 1.07M.
It is up +0.20% in the last 24 hours and up +2.53% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$71.56
Open:
$71.64
24h Volume:
1.07M
Relative Volume:
0.21
Market Cap:
$10.80B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.16
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+1.62%
1M Performance:
+2.53%
6M Performance:
+132.04%
1Y Performance:
+65.47%
1-Day Range:
$71.57
$71.78
1-Week Range:
$70.69
$71.78
52-Week Range:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
71.70 | 10.78B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire) - Aktiellt
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire) - Aktiellt
Update Recap: Can Avidity Biosciences Inc. stock sustain free cash flow growth2025 Risk Factors & Reliable Entry Point Alerts - BỘ NỘI VỤ
What analysts say about Avidity Biosciences Inc stockSwing Trading Watchlist & Investment Timing Techniques - earlytimes.in
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire) - Aktiellt
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal - BioSpace
Avidity Biosciences stock hits all-time high at 71.1 USD - Investing.com
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avidity Biosciences Inc Stock Analysis and ForecastStochastic Oscillator Alerts & Rapid Capital Trading - earlytimes.in
How Avidity Biosciences Inc. stock trades during market volatilityMarket Rally & Reliable Breakout Forecasts - newser.com
How Avidity Biosciences Inc. stock performs after earnings2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Key facts: Novartis to Acquire Avidity for $12B; Raises Sales Guidance - TradingView
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - BioSpace
Will Avidity Biosciences Inc. stock deliver long term returns2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Price action breakdown for Avidity Biosciences Inc.Quarterly Profit Review & Expert Approved Momentum Ideas - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Using AI based signals to follow Avidity Biosciences Inc.Quarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsIndex Update & Community Shared Stock Ideas - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock priceRate Cut & Low Drawdown Trading Techniques - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Avidity launches managed access program for DMD44 therapy By Investing.com - Investing.com Nigeria
Looking Into Avidity Biosciences Inc's Recent Short Interest - Benzinga
Avidity Biosciences announces U.S. Managed Access Program (MAP) for investigational therapy del-zota in DMD44 - MarketScreener
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44 - Investing News Network
Avidity launches managed access program for DMD44 therapy - Investing.com
Can Avidity Biosciences Inc. stock deliver sustainable ROEMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsJuly 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Avidity Biosciences Inc.Watch List & Daily Market Momentum Tracking - newser.com
Can Avidity Biosciences Inc. stock beat market expectations this quarterWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Why Avidity Biosciences Inc. stock attracts global investorsIndex Update & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc. stock ready for breakoutQuarterly Portfolio Summary & Intraday High Probability Alerts - newser.com
Visual analytics tools that track Avidity Biosciences Inc. performanceJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Real time alert setup for Avidity Biosciences Inc. performanceRate Hike & Entry Point Strategy Guides - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingM&A Rumor & Safe Swing Trade Setups - newser.com
Earnings visualization tools for Avidity Biosciences Inc.July 2025 Technicals & Verified Entry Point Signals - newser.com
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):